ATE197903T1 - Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken - Google Patents

Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken

Info

Publication number
ATE197903T1
ATE197903T1 AT93912042T AT93912042T ATE197903T1 AT E197903 T1 ATE197903 T1 AT E197903T1 AT 93912042 T AT93912042 T AT 93912042T AT 93912042 T AT93912042 T AT 93912042T AT E197903 T1 ATE197903 T1 AT E197903T1
Authority
AT
Austria
Prior art keywords
carbohydrate
peptide
cell immunity
effect
immunogenic
Prior art date
Application number
AT93912042T
Other languages
English (en)
Inventor
Mikael Jondal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE197903T1 publication Critical patent/ATE197903T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93912042T 1992-04-28 1993-04-23 Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken ATE197903T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv
PCT/SE1993/000353 WO1993021948A1 (en) 1992-04-28 1993-04-23 Peptide-carbohydrate conjugates generating t-cell immunity

Publications (1)

Publication Number Publication Date
ATE197903T1 true ATE197903T1 (de) 2000-12-15

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912042T ATE197903T1 (de) 1992-04-28 1993-04-23 Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken

Country Status (19)

Country Link
US (2) US5807559A (de)
EP (1) EP0675733B1 (de)
JP (1) JPH07506358A (de)
CN (1) CN1096032A (de)
AT (1) ATE197903T1 (de)
AU (1) AU676679B2 (de)
CA (1) CA2134097A1 (de)
DE (1) DE69329735T2 (de)
DK (1) DK0675733T3 (de)
ES (1) ES2155070T3 (de)
GR (1) GR3035501T3 (de)
IL (1) IL105503A (de)
IS (1) IS4010A (de)
MA (1) MA22885A1 (de)
MY (1) MY108864A (de)
PT (1) PT675733E (de)
SI (1) SI9300223A (de)
TN (1) TNSN93045A1 (de)
WO (1) WO1993021948A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
ES2265162T3 (es) * 1997-03-27 2007-02-01 Institut Pasteur Carbohidrato glucopeptido de antigeno multiple, vacuna que comprende el mismo y su utilizacion.
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
JP4308918B2 (ja) 1997-04-16 2009-08-05 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ （２，６）−ＳＴエピトープクラスターを有するα−Ｏ−結合複合糖質、その製造方法および使用
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
WO1999048515A1 (en) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
EP1068296B1 (de) 1998-03-31 2011-08-10 Geron Corporation Zusammensetzungen zur auslösung einer immunantwort gegen ein telomerase antigen
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
AU6921300A (en) * 1999-08-20 2001-03-19 Sloan-Kettering Institute For Cancer Research Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
EP1594898A2 (de) * 2003-02-06 2005-11-16 Tripep AB Glycosylierte spezifitätaustauscher
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
BRPI0611535B1 (pt) 2005-05-05 2021-11-30 Sensient Flavors Inc Método para processar células de levedura para produzir beta-glucanos e mananas
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
MX362513B (es) 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
EP2500033A1 (de) 2011-03-17 2012-09-19 Institut Pasteur Verfahren zur Herstellung mehrfacher Antigen-Glycopeptid-Kohlenhydratkonjugate
KR102436439B1 (ko) 2011-06-28 2022-08-25 이노비오 파마수티컬즈, 인크. 최소 침습 피부 전기천공 장치
EP2606897A1 (de) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Zusammensetzungen für die Behandlung von Krankheiten, die von eingehüllten Viren verursacht werden
WO2019014456A1 (en) * 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS HAVING A MUTATION H3K27M

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
EP0399001B1 (de) * 1988-02-01 1994-07-27 Praxis Biologics, Inc. T-zellen-epitope als träger für einen konjugierten impfstoff
WO1989007448A1 (en) * 1988-02-12 1989-08-24 Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
AU6272190A (en) * 1989-08-28 1991-04-08 Pierce Chemical Company Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
DE69329735T2 (de) 2001-08-02
IS4010A (is) 1993-10-29
CN1096032A (zh) 1994-12-07
DK0675733T3 (da) 2001-05-07
SI9300223A (en) 1994-03-31
PT675733E (pt) 2001-05-31
JPH07506358A (ja) 1995-07-13
EP0675733A1 (de) 1995-10-11
EP0675733B1 (de) 2000-12-06
AU676679B2 (en) 1997-03-20
DE69329735D1 (de) 2001-01-11
TNSN93045A1 (fr) 1994-03-17
MA22885A1 (fr) 1993-12-31
AU4274693A (en) 1993-11-29
IL105503A0 (en) 1993-08-18
CA2134097A1 (en) 1993-11-11
US6033669A (en) 2000-03-07
WO1993021948A1 (en) 1993-11-11
US5807559A (en) 1998-09-15
IL105503A (en) 1999-05-09
MY108864A (en) 1996-11-30
ES2155070T3 (es) 2001-05-01
GR3035501T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
ATE197903T1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
DK1036058T3 (da) Adamantanderivater
EE200000378A (et) Adamantaani derivaadid
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
DE68906366D1 (en) Cd4-polypeptidderivate.
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
CO4930281A1 (es) Conjugados utiles en el tratamiento del cancer de prostata
DE69527805D1 (de) Chemische mittel
DK602588D0 (da) Baerer-laegemiddelkonjugater, deres fremstiling og anvendelse som midler mod tumorer
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
HUT65418A (en) Process for producing inclusion compounds of nimesulide with cyclodextrins and pharmaceutical preparatives containing them
DK0822808T3 (da) Kompositmateriale med natriumstivelsesglycolat som bærermateriale og produkter deraf
SE9403905D0 (sv) New formulations
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
NO961204D0 (no) Triaryletylenderivater for anvendelse innen terapi
DK0934342T3 (da) Præparat indeholdende chitosan
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
PT92379A (pt) Metodo para a sintese de derivados polipeptidicos
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
NO884941L (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.
JP2002512261A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee